Technical Articles

This article systematically elaborates on the structural characteristics and immunogenicity of the myelin oligodendrocyte glycoprotein (MOG), the pathogenic mechanisms of MOG antibodies, and the historical evolution of detection methods for MOG antibody-associated disease (MOG-AD). It analyzes the diverse clinical phenotypes and imaging features of the disease across different age groups and discusses its treatment principles and prognosis.

This article systematically elaborates on the molecular basis and clinical characteristics of myelin oligodendrocyte glycoprotein immunoglobulin G antibody-associated disease (MOGAD) as an independent disease entity, analyzes its key differences from multiple sclerosis and neuromyelitis optica spectrum disorders, and introduces the diverse clinical manifestations, diagnostic points, and treatment strategies of MOGAD in different age groups.

Myelin oligodendrocyte glycoprotein (MOG) is a glycoprotein specifically expressed on the surface of oligodendrocytes and the outermost layer of myelin sheath in the central nervous system (CNS). As a member of the immunoglobulin superfamily, MOG consists of 218 amino acids.

Myelin oligodendrocyte glycoprotein (MOG) is an essential component of the outermost layer of myelin sheath in the central nervous system (CNS). Its molecular structure consists of 218 amino acids with a molecular weight of approximately 18-22 kDa, belonging to the immunoglobulin superfamily. MOG expression is highly specific, restricted to oligodendrocytes and the outermost myelin layer, constituting 0.01%-0.05% of total myelin proteins. This spatial distribution renders it a potential target for immune system attacks.

Multiple Sclerosis (MS) is a classic autoimmune disease whose pathological mechanisms are not yet fully understood. To further investigate and comprehend the pathogenesis of MS, researchers widely employ the Experimental Autoimmune Encephalomyelitis (EAE) animal model. In these models, Myelin Oligodendrocyte Glycoprotein (MOG) is utilized as an immunogen to induce autoimmune lesions, mimicking the progression of MS. This article reviews the establishment and characteristics of the MOG-induced EAE animal model, its applications in studying autoimmune diseases, and explores the potential role of this model in elucidating the pathophysiology of MS.